Integrin Molecules: A Clue to the Non-metastasizing Behaviour of Basal Cell Carcinomas?

H.-P. BAUM, T. SCHMID and J. REICHRATH

Department of Dermatology, University of Saarland, Occo-Orth-Strasse, Homburg/Saar, Germany

Does the integrin profile of basal cell carcinomas explain their non-metastasizing behaviour? Immunohistochemical investigation of nodular (n=31) and superficial (n=17) tumours yielded a strong expression of α2, α3, α6, β1, and β3 subunits and a weak expression of α4 subunits by the epithelial tumour component. α5 subunits were focally detected in superficial basal cell carcinomas but not in the nodular type. Tumour cells were nearly devoid of αv subunits.

The integrin profile of basal cell carcinomas does not differ essentially from that of metastasizing tumour varieties and cannot be regarded as a major reason for the non-metastasizing phenotype of basal cell carcinomas. Key words: skin; tumour; adhesion; invasion.

(Accepted August 15, 1995.)


H.-P. Baum, M.D., Department of Dermatology, University of Saarland, D-66421 Homburg/Saar, Germany.

One of the most fascinating biologic aspects of basal cell carcinomas (BCCs) is their non-metastasizing behaviour despite an overt invasive growth pattern. Hitherto, no satisfactory explanation of this paradox has been rendered. Following the metastatic cascade, tumour cells have to pass a sequence of steps which all require adhesion to and detachment from tumour cells, interstitial matrix proteins, connective tissue cells, and vessels. It is obvious that adhesion molecules play a key role during the metastatic process. The question, however, arises whether the profile of adhesion molecules is sufficient to explain the metastatic or non-metastatic phenotype of a tumour variety. Adding to former reports on the expression of integrins by basal cell carcinomas (1–7), we performed an immunohistochemical study on nodular and superficial BCCs (n=48) looking for the expression of α2, α3, α4, α5, α6, αv, β1, and β3 subunits. The question to be answered was: Does the integrin profile of BCCs account for their non-metastasizing behaviour?

MATERIAL AND METHODS

Tissue samples

Slices (2 mm wide) of freshly excised nodular (n=31) and superficial (n=17) BCCs were snap-frozen in liquid nitrogen. Cryostat sections (5 μm) were mounted on poly-L-lysine (Sigma P 1399, Deisenhofen, Germany) coated slides and air-dried (2 h, room temperature [RT]) followed by fixation in acetone (10 min, 4°C), air drying (a few minutes) and rinsing in 0.19 M Tris buffered saline (TBS), pH 7.4 (5 min, RT).

Immunohistochemical labelling

Background staining was blocked with heat-inactivated normal rabbit serum (DAKO X 902, Hamburg, Germany) or normal goat serum (DAKO X 907) diluted 1:1 in 0.19 M TBS, pH 7.4 (30 min, RT).

A panel of monoclonal antibodies was used, directed against the following integrin subunits:

- α 2 subunit (mouse mAb, clone G9; dianova 0717, Hamburg, Germany);
- α 3 subunit (mouse mAb, clone M-KID2; dianova 1308);
- α 4 subunit (mouse mAb, clone HP2.1; dianova 0764);
- α 5 subunit (mouse mAb, clone SAM1; dianova 0771);
- α 6 subunit (rat mAb, clone GoH3; dianova 0769);
- αv subunit (mouse mAb, clone AMF7, dianova 0770);
- β 1 subunit (mouse mAb, clone K20; dianova 1151);
- β 3 subunit (mouse mAb, clone S22; dianova 0540).

The primary antibodies were diluted 1:100 in 0.19 M TBS, pH 7.4, with 1% BSA (Sigma A 9647) added, and were applied to the sections for 30 min at RT. Monoclonal mouse antibodies were detected with biotinylated rabbit-anti-mouse bridge antibody 1:400 (DAKO M 413), 30 min, RT, followed by streptavidin-peroxidase 1:400 (DAKO P 397), 30 min, RT. For detection of the rat mAb biotinylated goat-anti-rat bridge antibody 1:400 (dianova 112-466-062) was applied. AEC (Sigma A 5754) was used to visualize the peroxidase reaction. For negative controls, the primary antibodies were left out. No background staining was observed.

RESULTS

BCCs of the nodular and superficial type displayed a distinct and differential profile of integrins. Strong expression of the α 2 and α 3 subunits was found in a pericellular distribution on the tumour cells. The labelling was most intense at the periphery of the tumour strands and declined towards their central parts. Groups of BCC cells that failed to express α 2 or α 3 subunits were found within the palisaded zone of the tumour islands (Fig. 1). The αv subunit was expressed very faintly and only focally by BCC cells. Tumour cell nests of nodular BCCs were devoid of α 5 subunits in contrast to superficial BCC aggregates (Figs. 2 and 3). In the latter variety, a focal intercellular expression of α 5 was detected in addition to a discontinuous labelling pattern of the BCC basement membrane. (Fig. 3). α 5 subunits were richly

---

Fig. 1. Nodular BCC. α 2 subunit of VLA-integrin (streptavidin-biotin-Pox, ×220).

© 1996 Scandinavian University Press. ISSN 0001-5555
expressed by stromal cells and blood capillaries. As to the α 6 subunit, a staining pattern similar to α 2 and α 3 was found, i.e. a strong pericellular expression of α 6 by the peripheral tumour cells and a decreased labelling intensity of the centrally located cells (Fig. 4). The stromal capillaries exhibited a strong staining reaction for α 6. The α 5 subunit of the vitronectin receptor was hardly detectable in the epithelial component of BCCs. Instead, there was an intense labelling of stromal elements (fibroblasts and blood vessels) (Fig. 5). The β 1 and β 3 integrin subunits were distributed in a pericellular fashion on the surfaces of most of the BCC cells. There was a focal decrease or lack of immunoreactivity in central parts of the tumour strands (Fig. 6). The fibroblasts and the blood vessels of the BCC stroma displayed an intense staining reaction for both the β 1 and β 3 subunits. The staining patterns of the integrin subunits were uniform in all parts of the same tumour specimen. As to our observation, the expression of α 2, α 3, α 4, α 6, α 5, β 1, and β 3 subunits did not correlate with the growth pattern or eventual inflammatory infiltrates of BCCs. In contrast, the α 5 subunit was restricted to superficial BCCs, where it could focally be detected between tumour cells and along the BCC basement membrane.

DISCUSSION

Our investigation was prompted by the question whether the integrin profile of BCCs could give an explanation of their non-metastasizing behaviour. In accordance with former studies (1–4, 6, 7) we found a strong expression of α 2, α 3, β 1,
and β3 subunits. As a rule, the peripheral cell rows of the tumour strands displayed a more intense labelling than the inner parts. Occasional cell groups devoid of any α or β subunits were mentioned by Stamp & Pignatelli (2). We confirm this observation as a consistent finding in nodular BCCs and explain it by a focal keratotic differentiation. In contrast, the fading of integrin subunits from the central parts of BCC strands might be due to a reduced functional performance of these tumour cells. As to the α5 subunit, our results indicate that BCCs of the superficial type synthesize this molecule, which is not expressed in BCCs of the nodular variety or in epidermal keratinocytes. Savoia et al. (6) did not detect the α5 subunit in BCCs but Peltonen et al. (1) and Tuominen et al. (7) reported a weak and focal expression of α5 subunits by the tumour cells. Savoia et al. (6) and we ourselves had used the same mAb (clone SAM-1), whereas Peltonen et al. (1) and Tuominen et al. (7) had applied different α5 antibodies (mAb rAT IgG2a (1), and mAb mouse PI D6 (7)). The difference between our findings and those of Peltonen et al. (1) and Tuominen et al. (7) as to the α5 expression could also be due to the tissue preparation (no fixation of the cryostat sections in 1, 7 vs. acetone fixation in our investigation). Savoia et al. (6), however, using unfixed sections like 1, 7 found the same staining pattern as we did. That is the reason why we estimate the absence of the α5 antibody to be the salient point, explaining the different α5 immunoreactivity. The α4 subunit was found to be negative (6) or positive (7) in BCCs. We detected a faint and heterogeneous immunoreactivity for α4 subunits. The epithelial component of BCCs proved to be almost negative for the αv subunit but the tumour stroma abounded with αv immunoreactivity. Tuominen et al. (7) reported αv expression by BCC cells. Our result of a strong α6 labelling of tumour cells stands out against the findings of Korman & Harbovsky (4), Savoia et al. (6), and Tuominen et al. (7). These investigators state that BCC cells are devoid of α6 or express it only focally in minor amounts. We applied an anti-α6 mAb (rat IgG2a) derived from the same clone (GoH3) as used by Savoia et al. (5) and Tuominen et al. (7). A second series of immunolabelling experiments at our laboratory using a different lot of anti-α6 mAb (clone GoH3) yielded the same staining pattern as before. The distinct and reproducible staining result cannot be regarded as an artefact. By that, we estimate the question of α6 expression by BCCs not yet to be settled. Except for the α4β1 integrin, which binds to VCAM-1 expressed on activated endothelial cells, all the other α and β subunits studied are components of integrins binding to extracellular matrix (ECM) proteins (collagen type I and type IV, fibronectin, vitronectin, laminin, fibrinogen) (8). By their differentiated profile of integrins, BCCs may form multiple contacts to stromal elements. The functional repertoire of integrins, however, includes intercellular adhesion (9, 10) and receptor functions initiating intracellular phosphorylation processes (11) or synthesis of collagenase (12). The activity of an integrin molecule itself is dependent on the state of phosphorylation, cytoskeletal association, or clustering within the cell membrane (8, 11). The expression of VLA-integrins and components of the vitronectin receptor on BCC cells not in contact with ECM proteins argues against the simple hypothesis that these membrane compounds merely mediate epithelial-stromal interactions. The ligand specificity and the intracellular processes subsequent to ligand binding strongly depend on the type of tumour cell and its environmental conditions (10, 13).

Does the pattern of integrins expressed by BCCs explain their non-metastasizing behaviour? No, it does not. BCCs exhibit principally the same adhesion molecules as metastasizing tumour varieties like malignant melanomas (13–15). The very low expression of α4 subunits in comparison with melanoma cells is an unfavourable precondition for the adherance of BCC cells to activated endothelial cells via VCAM-1. It is, however, not proven that non-lymphoid tumour cells make use of this adhesion mechanism for intra- or extravasation. Taraboletti et al. (16) suggest that the formation of metastases may depend much more upon tumour cell adhesion to subendothelial basement membrane components than to the endothelium itself.

Savoia et al. (5) speculate that the simultaneous absence of a hemidesmosomal integrin (α6β4) and its basement membrane ligand (BM-600, nicoxin) might play a role for the benign course of BCCs. It is clear that the quantity of integrin receptors differentially regulates the performance of cells. Up to now, however, it has not been demonstrated that quantitative differences of integrin profiles determine a metastatic vs. non-metastatic phenotype of tumour cells (15).

ACKNOWLEDGEMENT

This investigation was supported by a grant from the Medical Faculty, University of Saarland, Germany.

REFERENCES


* Acta Derm Venereol (Stockh) 76*
adhesion to basal lamina. Proc Natl Acad Sci USA 1990; 87: 6888–6892.


